ALIVUS LIFE SCIENCES LTD Fair Value
ALIVUS · Healthcare · Current price ₹1,447.2
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹423 | 17% ROE fading to 12% over ~20 yrs, on ₹272 book |
| Relative P/E | ₹1,394 | EPS × 30.3 peer-median P/E |
| Graham floor | ₹530 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹1,397 | Street consensus 12-month target price |
Is ALIVUS LIFE SCIENCES LTD undervalued?
DocStoX estimates the fair value of ALIVUS LIFE SCIENCES LTD at ₹836 per share, versus the current market price of ₹1,447. That puts the stock about -42.3% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹423), Relative P/E (₹1,394), Graham floor (₹530), Analyst target (₹1,397). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹423 (bear) to ₹836 (base) to ₹1,397 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on ALIVUS LIFE SCIENCES LTD
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.